Roche is trying to offer a solution for patient selection in immunooncology. At the ESMO congress in Madrid, the theranostics company presented a liquid biopsy test that measures the tumour mutational burden in order to predict the probability for response to immunotherapy.
Portuguese and Swiss scientists have discovered that neurons located at mucosal tissues can immediately detect an infection in the organism, promptly producing a substance that acts as an "adrenaline rush" for immune cells.
Belgian diagnostics company MDxHealth SA has appointed Michael K. Brawer, MD as Chief Medical Officer to prepare the company for growth in H2/17 and beyond. The urologist and former professor of urology and pathology has over 25 years of experience in the industry leading clinical affairs in urology for diagnostic and pharmaceutical companies. Before joining MDx Health, Brawer served as Vice President of Medical Affairs, Urology at Myriad Genetics where he led all clinical aspects of development, education and commercialisation of Myriad’s prognostic prostate cancer assay. Prior to that, he held senior positions for GTx Inc, Tokai Pharmaceuticals and Threshold Pharmaceuticals. "Dr. Brawer’s arrival rounds out our 2017 campaign to expand our executive team, alongside our goal to nearly double our US sales force, in preparation for a sustained growth phase", commented Dr. Jan Groen, CEO, MDxHealth.
Swiss cancer vaccine developer AMAL Therapeutics has raised €8m in a Series B round led by existing investor Boehringer Ingelheim Venture Fund, and new investors BioMedPartners and Helsinn Investment Fund.
Six European states, together with the Wellcome Trust, and South Africa have pledged €56.5m to help develop new antibiotics that break resistance.
The Allegro STR bioreactor family combines Pall’s bioprocess engineering expertise, cell culture know-how and our drive for quality into a series of single-use bioreactors that deliver consistent and scalable cell culture performance across the range.
Researchers at the University of Sussex have invented a new algorithm that could revolutionise patient monitoring and activity tracking.
French Ajinomoto Eurolysine SAS, part of the world leading producer of amino acids by fermentation, has received a positive safety assessment from the European Food Safety Authority (EFSA) for use of freeze-dried genetically modified E. coli bacteria as a feedstuff supplement.